Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?

1 Jul 2024

Abstract excerpt

Adeno-associated virus (AAV) mediated gene therapy is a leading gene delivery platform with potential to transform the landscape of treatment for neurological disorders. While AAV is deemed non-immunogenic compared to other viral vectors, adverse immune reactions have been observed in the clinic, raising concerns. As the central nervous system (CNS) has a tightly regulated immune system, characterized by a degree...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA Interference and Gene Delivery
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39180957
DOI: 10.1016/j.neurot.2024.e00435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?PMID 39180957Read ↗

Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and ApproachesSemantic proximity Read ↗

Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedsideSemantic proximity Read ↗

Routes of administration for adeno-associated viruses carrying gene therapies for brain diseasesSemantic proximity Read ↗

Adeno-Associated Virus (AAV) Vectors in the CNSSemantic proximity Read ↗

Characterization of Immune Responses to rAAVrh8 Gene Therapy for GM2 Gangliosidosis in Phase 1/2 TrialSemantic proximity Read ↗

Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular DisordersSemantic proximity Read ↗

Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus VectorsSemantic proximity Read ↗

Adeno-associated virus therapies: Pioneering solutions for human genetic diseasesSemantic proximity Read ↗

Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.Semantic proximity Read ↗

Characterization of Immune Responses to rAAVrh8 Gene Therapy for GM2 Gangliosidosis in Phase 1/2 TrialSemantic proximity Read ↗

Biology of adeno-associated viral vectors in the central nervous systemSemantic proximity Read ↗

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.